LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trialD. Schadendorf, E. Livingstone, Thomas Eigentler et al.|Annals of Oncology|2024Cited by 3
Genetic characterization and clinical outcome of melanoma of unknown primary (MUP) with comparison to melanoma with known primary (MKP)Georg Lodde, E. Livingstone, J. Dollani et al.|EJC Skin Cancer|2025Cited by 0